Header

Melanoma Clinical Trials

Category:Adult
Status:Active

Displaying all 11 trials

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating pati...

Diagnosis: Melanoma, Cutaneous Skin Cancer

Phase: 2 / 3

Protocol Number: 15-724

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. T...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 15-012

Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma

This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases from Melanoma. The names of the study interventions involved in this study are: - Ip...

Diagnosis: Melanoma

Phase: 2

Protocol Number: 16-136

RTA 408 Capsules in Patients With Melanoma - REVEAL

Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths. For metastatic or unresectable melanomas, standard ...

Diagnosis: Melanoma

Phase: 1 / 2

Protocol Number: 15-215

Dendritic Cell Activating Scaffold in Melanoma

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investi...

Diagnosis: Melanoma

Phase: 1

Protocol Number: 12-306

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to ...

Diagnosis: Melanoma

Phase: 1

Protocol Number: 13-304

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

The purpose of this study is to determine the initial safety profile of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab] with investigational drugs [TAK-580, TAK-202...

Diagnosis: Melanoma

Phase:

Protocol Number: 16-269

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The intervention...

Diagnosis: Melanoma

Phase:

Protocol Number: 17-030

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with P...

Diagnosis: GYN: Endometrial/Uterine Cancer, Melanoma, Pancreatic Cancer, Breast: Early Stage Disease

Phase:

Protocol Number: 16-491

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: - Pembrolizumab (Keytruda) - Trametinib...

Diagnosis: Melanoma

Phase:

Protocol Number: 16-642

Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)

Phase 1b Subjects will be treated with talimogene laherparepvec until all injectable tumors have disappeared, disease progression per modified Immune-Related Response Criteria (irRC), or intoleranc...

Diagnosis: Melanoma

Phase:

Protocol Number: 16-405

'